DDInter504 DDInter465
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.
Desipramine {u} (Compound) resembles {v} (Compound) Trimipramine
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Trimipramine
Trimipramine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Desipramine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Desipramine {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Desipramine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may lead to a major life threatening interaction when taken with Dacomitinib
Desipramine (Compound) resembles Trimipramine (Compound) and Trimipramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Desipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Desipramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Desipramine (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Dacomitinib